By Ben Glickman

Shares of Cytokinetics jumped Monday after the Wall Street Journal reported the company was close to being bought by Novartis.

The stock was up 16% to $109.22 after the news broke, reversing declines earlier in the day. Shares have more than doubled in the last year.

A deal could be finalized as soon as this week, people familiar with the situation told WSJ. Cytokinetics has been running a sale process and another buyer could potentially emerge.

Novartis shares were down 0.4% to $105.90.

Cytokinetics shares surged last month after releasing positive data for a potential treatment for hypertrophic cardiomyopathy, a genetic heart condition.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

January 08, 2024 13:28 ET (18:28 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Novartis 차트를 더 보려면 여기를 클릭.
Novartis (NYSE:NVS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Novartis 차트를 더 보려면 여기를 클릭.